Silent Celiac Disease in Chronic Hepatitis C: Impact of Interferon Treatment on the Disease Onset and Clinical Outcome

[Guest guest]

Clin Gastroenterol. 2004 Nov;38(10):901-905.

Silent Celiac Disease in Chronic Hepatitis C: Impact of Interferon Treatment

on the Disease Onset and Clinical Outcome.

Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, Ruggiero

G, Adinolfi LE.

From the Divisions of *Internal Medicine and Hepatology, daggerLaboratory

Medicine, and double daggerImmuno-Hematology, Second University of Naples

Medical School, Napoli, Italy.

GOALS:: To assess the impact of interferon treatment on celiac disease onset

in hepatitis C patients and to clarify its clinical relevance and outcome.

BACKGROUND:: Hepatitis C is associated with autoimmunity, which can be

exacerbated by interferon treatment. Cases of celiac disease activation

during interferon treatment have been reported. STUDY:: Retrospective

evaluation of 534 hepatitis C patients with or without symptoms compatible

with celiac disease onset during interferon treatment and 225 controls.

Anti-transglutaminase antibodies were assayed. HLA-DQA1 and -B1 loci were

typed. Upper gastrointestinal endoscopy was applied to confirm the diagnosis

in antibody-positive patients. RESULTS:: Anti-transglutaminase antibodies

were detected before treatment in 1.3% of hepatitis C patients and in 0.4%

of controls (not significant). Eighty-six percent of patients with

anti-transglutaminase antibodies showed activation of celiac disease while

on interferon. Symptoms ranged from mild to severe, and interferon had to be

discontinued in 2 of 7 (29%) patients. Symptoms disappeared in 6 of 7

patients after interferon withdrawal. Onset of symptoms compatible with

celiac disease during interferon therapy was significantly associated with

the presence of anti-transglutaminase antibodies (OR 53). CONCLUSIONS:: In

hepatitis C patients, the activation of silent celiac disease during

interferon treatment is almost universal and should be suspected, but it

uncommonly requires interferon treatment discontinuation. Symptoms subside

after interferon withdrawal.

PMID: 15492610 [PubMed - as supplied by publisher]

[Guest guest]

Clin Gastroenterol. 2004 Nov;38(10):901-905.

Silent Celiac Disease in Chronic Hepatitis C: Impact of Interferon Treatment

on the Disease Onset and Clinical Outcome.

Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, Ruggiero

G, Adinolfi LE.

From the Divisions of *Internal Medicine and Hepatology, daggerLaboratory

Medicine, and double daggerImmuno-Hematology, Second University of Naples

Medical School, Napoli, Italy.

GOALS:: To assess the impact of interferon treatment on celiac disease onset

in hepatitis C patients and to clarify its clinical relevance and outcome.

BACKGROUND:: Hepatitis C is associated with autoimmunity, which can be

exacerbated by interferon treatment. Cases of celiac disease activation

during interferon treatment have been reported. STUDY:: Retrospective

evaluation of 534 hepatitis C patients with or without symptoms compatible

with celiac disease onset during interferon treatment and 225 controls.

Anti-transglutaminase antibodies were assayed. HLA-DQA1 and -B1 loci were

typed. Upper gastrointestinal endoscopy was applied to confirm the diagnosis

in antibody-positive patients. RESULTS:: Anti-transglutaminase antibodies

were detected before treatment in 1.3% of hepatitis C patients and in 0.4%

of controls (not significant). Eighty-six percent of patients with

anti-transglutaminase antibodies showed activation of celiac disease while

on interferon. Symptoms ranged from mild to severe, and interferon had to be

discontinued in 2 of 7 (29%) patients. Symptoms disappeared in 6 of 7

patients after interferon withdrawal. Onset of symptoms compatible with

celiac disease during interferon therapy was significantly associated with

the presence of anti-transglutaminase antibodies (OR 53). CONCLUSIONS:: In

hepatitis C patients, the activation of silent celiac disease during

interferon treatment is almost universal and should be suspected, but it

uncommonly requires interferon treatment discontinuation. Symptoms subside

after interferon withdrawal.

PMID: 15492610 [PubMed - as supplied by publisher]

[Guest guest]

Clin Gastroenterol. 2004 Nov;38(10):901-905.

Silent Celiac Disease in Chronic Hepatitis C: Impact of Interferon Treatment

on the Disease Onset and Clinical Outcome.

Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, Ruggiero

G, Adinolfi LE.

From the Divisions of *Internal Medicine and Hepatology, daggerLaboratory

Medicine, and double daggerImmuno-Hematology, Second University of Naples

Medical School, Napoli, Italy.

GOALS:: To assess the impact of interferon treatment on celiac disease onset

in hepatitis C patients and to clarify its clinical relevance and outcome.

BACKGROUND:: Hepatitis C is associated with autoimmunity, which can be

exacerbated by interferon treatment. Cases of celiac disease activation

during interferon treatment have been reported. STUDY:: Retrospective

evaluation of 534 hepatitis C patients with or without symptoms compatible

with celiac disease onset during interferon treatment and 225 controls.

Anti-transglutaminase antibodies were assayed. HLA-DQA1 and -B1 loci were

typed. Upper gastrointestinal endoscopy was applied to confirm the diagnosis

in antibody-positive patients. RESULTS:: Anti-transglutaminase antibodies

were detected before treatment in 1.3% of hepatitis C patients and in 0.4%

of controls (not significant). Eighty-six percent of patients with

anti-transglutaminase antibodies showed activation of celiac disease while

on interferon. Symptoms ranged from mild to severe, and interferon had to be

discontinued in 2 of 7 (29%) patients. Symptoms disappeared in 6 of 7

patients after interferon withdrawal. Onset of symptoms compatible with

celiac disease during interferon therapy was significantly associated with

the presence of anti-transglutaminase antibodies (OR 53). CONCLUSIONS:: In

hepatitis C patients, the activation of silent celiac disease during

interferon treatment is almost universal and should be suspected, but it

uncommonly requires interferon treatment discontinuation. Symptoms subside

after interferon withdrawal.

PMID: 15492610 [PubMed - as supplied by publisher]

[Guest guest]

Clin Gastroenterol. 2004 Nov;38(10):901-905.

Silent Celiac Disease in Chronic Hepatitis C: Impact of Interferon Treatment

on the Disease Onset and Clinical Outcome.

Durante-Mangoni E, Iardino P, Resse M, Cesaro G, Sica A, Farzati B, Ruggiero

G, Adinolfi LE.

From the Divisions of *Internal Medicine and Hepatology, daggerLaboratory

Medicine, and double daggerImmuno-Hematology, Second University of Naples

Medical School, Napoli, Italy.

GOALS:: To assess the impact of interferon treatment on celiac disease onset

in hepatitis C patients and to clarify its clinical relevance and outcome.

BACKGROUND:: Hepatitis C is associated with autoimmunity, which can be

exacerbated by interferon treatment. Cases of celiac disease activation

during interferon treatment have been reported. STUDY:: Retrospective

evaluation of 534 hepatitis C patients with or without symptoms compatible

with celiac disease onset during interferon treatment and 225 controls.

Anti-transglutaminase antibodies were assayed. HLA-DQA1 and -B1 loci were

typed. Upper gastrointestinal endoscopy was applied to confirm the diagnosis

in antibody-positive patients. RESULTS:: Anti-transglutaminase antibodies

were detected before treatment in 1.3% of hepatitis C patients and in 0.4%

of controls (not significant). Eighty-six percent of patients with

anti-transglutaminase antibodies showed activation of celiac disease while

on interferon. Symptoms ranged from mild to severe, and interferon had to be

discontinued in 2 of 7 (29%) patients. Symptoms disappeared in 6 of 7

patients after interferon withdrawal. Onset of symptoms compatible with

celiac disease during interferon therapy was significantly associated with

the presence of anti-transglutaminase antibodies (OR 53). CONCLUSIONS:: In

hepatitis C patients, the activation of silent celiac disease during

interferon treatment is almost universal and should be suspected, but it

uncommonly requires interferon treatment discontinuation. Symptoms subside

after interferon withdrawal.

PMID: 15492610 [PubMed - as supplied by publisher]